

InvitroCue Limited

ASX: IVQ

Transforming Bio-Analytics

**Corporate Structure:**

Shares on issue: 444M  
Market Cap: \$44.4 M

**Directors:**

**Dr Steven Fang**  
Founder & Executive Director

**Ms Jamie Khoo**  
Non-Executive Chairman

**Mr Chow-Yee Koh**  
Executive Director & Company Secretary

**Registered Office:**  
Level 2, 350 Kent St.  
Sydney NSW 2000 Australia

**Singapore Office:**  
11 Bioplis Way  
Helios 12-07/08  
Singapore 138667

**Email:**  
contact@invitrocue.com

**Website:**  
www.invitrocue.com

## InvitroCue expands laboratory in Suzhou for full cell-based assaying offering in China

- Expansion of laboratory facility in China to greatly enhance Company's current service offerings
- Suzhou laboratory facility to support local and multinational companies in developing and testing new drugs and cosmetic products
- Enables IVQ to meet future growth of drug development in China

**07 March 2016, Suzhou & Sydney:** The Directors of InvitroCue Limited (formerly Bunuru Corporation Limited) (ASX:IVQ) ("InvitroCue" or "the Company") are pleased to announce the expansion of the Company's laboratory facility in Suzhou, China.

IVQ's Suzhou laboratory facility now provide a full service offering of cell-based assaying services to cater for biopharmaceutical clients in Suzhou Industrial Park and the Greater Shanghai Area. The Suzhou facility will also enable InvitroCue to support the needs of the Company's multinational client base with operations in China.

The expansion is the first in IVQ's investment foray into China, which now boasts the world's second largest healthcare market. Forecasted spending on pharmaceuticals is set to reach \$155 to \$185 billion by 2018 according to IMS Health.

The Company has witnessed significant opportunities in the region due to a move away from animal testing of products such as toiletries, lipsticks, moisturisers and other beauty products.

InvitroCue Executive Director Dr Steven Fang commented: "We are pleased to broaden our service offering to the Chinese market. For the past few years we have worked extensively in Singapore to further enhance and develop our *in vitro* technology and we are now very well positioned to harness a potentially large market opportunity presented by China."

"By establishing our cell-based assaying services in China, we are continuing to push the movement away from animal testing and simultaneously providing our clients with an efficient, cheaper and faster way to test their products."

"We are also currently assessing a number of strategic collaborations and joint ventures with Chinese partners, and I look forward to updating shareholders on our progress in this regard in the near future."

— ENDS —

**For further information, please contact:**

Dr Steven Fang  
Executive Director  
Steven.fang@invitrocue.com

**Released through:**

Adam Jarvis, Six Degrees Investor Relations: +61 427 297 736 or  
adam.jarvis@sdir.com.au